Your browser doesn't support javascript.
loading
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari, Ajai; Cornell, Robert F; Gasparetto, Cristina; Karanes, Chatchada; Matous, Jeffrey V; Niesvizky, Ruben; Lunning, Matthew; Usmani, Saad Z; Anderson, Larry D; Chhabra, Saurabh; Girnius, Saulius; Shustik, Chaim; Stuart, Robert; Lee, Yihua; Salman, Zeena; Liu, Emily; Valent, Jason.
Afiliación
  • Chari A; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York.
  • Cornell RF; Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Duke University Health System, Durham, North Carolina.
  • Karanes C; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
  • Matous JV; Department of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, Colorado.
  • Niesvizky R; Department of Medical Oncology, Weill Cornell Medicine, New York, New York.
  • Lunning M; Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, Nebraska.
  • Usmani SZ; Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
  • Anderson LD; Division of Hematology Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.
  • Chhabra S; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Girnius S; Department of Medicine, University of Cincinnati Cancer Institute, Cincinnati, Ohio.
  • Shustik C; Division of Hematology, Cedars Cancer Centre, McGill University Health Centre, Montreal, Quebec, Canada.
  • Stuart R; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina.
  • Lee Y; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.
  • Salman Z; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.
  • Liu E; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California.
  • Valent J; Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio.
Hematol Oncol ; 38(3): 353-362, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32053229
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Mieloma Múltiple / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Mieloma Múltiple / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido